These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 37147855

  • 1. Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.
    Reich A, Pinter A, Maul JT, Vender RB, Torres T, Brnabic A, Haustrup N, Reed C, Schuster C, Riedl E.
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1825-1840. PubMed ID: 37147855
    [Abstract] [Full Text] [Related]

  • 2. Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.
    Armstrong A, Puig L, Langley R, Tsai TF, Song M, Wasfi Y, Jiang J, Li S, Han C.
    J Dermatolog Treat; 2019 Feb; 30(1):27-34. PubMed ID: 28797188
    [Abstract] [Full Text] [Related]

  • 3. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
    Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
    [Abstract] [Full Text] [Related]

  • 4. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
    Lynde C, Riedl E, Maul JT, Torres T, Pinter A, Fabbrocini G, Daniele F, Brnabic A, Reed C, Wilhelm S, Holzkämper T, Schuster C, Puig L.
    Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
    [Abstract] [Full Text] [Related]

  • 5. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA.
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO).
    Travaglini M, Maul JT, Kors C, Zaheri S, Gerwien J, Müller M, Brnabic A, Sabatino S, Schuster C, Tsai TF.
    Clin Cosmet Investig Dermatol; 2023 Feb; 16():2971-2983. PubMed ID: 37881205
    [Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
    Pinter A, Puig L, Schäkel K, Reich A, Zaheri S, Costanzo A, Tsai TF, Smith SD, Lynde C, Brnabic A, Reed C, Hill J, Schuster C, Riedl E, Paul C.
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
    Pinter A, Eyerich K, Costanzo A, Garrelts A, Schuster C, Mert C, Lampropoulou A, Fotiou K, Maul JT, Papp KA.
    J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
    [Abstract] [Full Text] [Related]

  • 11. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.
    Puig L, Costanzo A, de Jong EMGJ, Torres T, Warren RB, Wapenaar R, Wegner S, Gorecki P, Gramiccia T, Jazra M, Buyze J, Conrad C.
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2539-2558. PubMed ID: 39153060
    [Abstract] [Full Text] [Related]

  • 12. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
    Papp KA, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, Beaumont JL, Pham TP, Kisa R, Napoli AA, Banerjee S, Armstrong AW.
    JAMA Dermatol; 2024 Feb 01; 160(2):204-209. PubMed ID: 38117487
    [Abstract] [Full Text] [Related]

  • 13. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
    Gerdes S, Bräu B, Hoffmann M, Korge B, Mortazawi D, Wiemers F, Wegner S, Personke Y, Gomez M, Sticherling M.
    J Dermatol; 2021 Dec 01; 48(12):1854-1862. PubMed ID: 34510527
    [Abstract] [Full Text] [Related]

  • 14. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 01; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 15. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.
    Mathias SD, Feldman SR, Crosby RD, Colwell HH, McQuarrie K, Han C.
    J Dermatolog Treat; 2016 Aug 01; 27(4):322-7. PubMed ID: 26634943
    [Abstract] [Full Text] [Related]

  • 16. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S, Kanai Y, Murotani K, Nomura T, Ito K, Ohata C, Yamazaki F, Miyagi T, Takahashi H, Okubo Y, Saeki H, Honma M, Tada Y, Mabuchi T, Higashiyama M, Kobayashi S, Hashimoto Y, Seishima M, Kakuma T.
    J Dermatol Sci; 2021 Mar 01; 101(3):185-193. PubMed ID: 33495058
    [Abstract] [Full Text] [Related]

  • 17. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
    Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R.
    J Eur Acad Dermatol Venereol; 2018 Aug 01; 32(8):1305-1313. PubMed ID: 29512200
    [Abstract] [Full Text] [Related]

  • 18. Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO.
    Riedl E, Pinter A, Zaheri S, Costanzo A, Brnabic A, Konicek B, McKenzie R, Lampropoulou A, Rayes ME, Haustrup N, Schuster C.
    Dermatol Ther (Heidelb); 2024 May 01; 14(5):1327-1335. PubMed ID: 38649673
    [Abstract] [Full Text] [Related]

  • 19. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).
    Piaserico S, Riedl E, Pavlovsky L, Vender RB, Mert C, Tangsirisap N, Haustrup N, Gallo G, Schuster C, Brunner PM.
    Front Med (Lausanne); 2023 May 01; 10():1185523. PubMed ID: 37457564
    [Abstract] [Full Text] [Related]

  • 20. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.
    J Dermatol Sci; 2020 Jul 01; 99(1):53-61. PubMed ID: 32600737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.